
    
      The primary objective of this study is assess the bioequivalence of two premixed formulations
      of insulin Lispro, Humalog Mix50/50® and ListroMix 50/50® in healthy subjects based on the
      pharmacokinetic parameter (PK) AUC (INS-LIS 0-20h) and the pharmacodynamic parameter (PD) AUC
      (GIR 0-20h) and also assess the safety and local tolerability of the two insulin
      preparations.
    
  